Materiały źródłowe

• #1 Medical Management – Lambert-Eaton Myasthenic Syndrome (LEMS) – Diseases | Muscular Dystrophy Association

  https://www.mda.org/disease/lambert-eaton-myasthenic-syndrome/medical-management

  There is no cure for Lambert-Eaton mysathenic syndrome (LEMS), as scientists have not yet figured out how to selectively stop the autoimmune attack on motor nerve terminal calcium channels and other nerve terminal proteins targeted by LEMS. Therefore, symptomatic treatments for neuromuscular weakness that results from LEMS are favored. […] Firdapse (also known as 3,4-diaminopyridine, 3,4-DAP) was approved by the FDA in November 2018 for the treatment of adults with LEMS and is commercialized by Catalyst Pharmaceuticals. […] Cholinesterase inhibitors are usually only mildly effective for LEMS, but in rare cases they can prove sufficient for managing the disease. […] Drugs that suppress the immune system can be used to attack the autoimmune nature of LEMS, but they have side effects and increase susceptibility to infections and, possibly, cancer.

• #1 Lambert-Eaton Syndrome Treatments | AmeriPharma™ Specialty

  https://ameripharmaspecialty.com/lambert-eaton-syndrome/a-guide-to-treatments-for-lambert-eaton-syndrome/

  Lambert-Eaton syndrome is a rare and progressive disease affecting over two million people worldwide. It can cause muscle weakness by disrupting neuromuscular function. There are many treatments for Lambert-Eaton syndrome. However, their efficacy varies among patients. […] Here, we will look closer at the treatment of Lambert-Eaton syndrome with different forms of therapy. From medications to surgery and IVIG infusions, we will introduce you to the most effective treatments for this disease to help you make an informed decision for your health. […] LEMS has no cure yet, but several treatments can alleviate its symptoms and help patients live a relatively normal life. Here are the most effective treatments for LEMS. […] Treatment of Lambert-Eaton syndrome depends on the patient’s underlying health conditions. Since 60% of LEMS patients have an associated small-cell lung cancer, the first approach is to treat the cancer.

• #1 Lambert-Eaton myasthenic syndrome

  https://www.nhs.uk/conditions/lambert-eaton-myasthenic-syndrome/

  There’s currently no cure for LEMS, but a number of treatments can help reduce the symptoms. […] These include: […] treatment for lung cancer if you have lung cancer, treating it can significantly improve the symptoms of LEMS […] medicine to help nerve signals reach the muscles commonly used medicines include 3,4-diaminopyridine and pyridostigmine […] medicine to reduce the activity of the immune system (immunosuppressants) commonly used medicines include steroid tablets (such as prednisolone), azathioprine and methotrexate […] plasmapheresis a procedure to redirect your blood through a machine that filters out the antibodies attacking your nerves […] immunoglobulin therapy injections of antibodies from donated blood that temporarily stop your immune system attacking your nerves. […] Medicine is the main treatment, although plasmapheresis and immunoglobulin therapy may be recommended in the short term, or if muscle weakness is severe and other treatments have not helped.

• #1 Lambert–Eaton myasthenic syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Lambert%E2%80%93Eaton_myasthenic_syndrome

  If the disease is associated with cancer, direct treatment of the cancer often relieves the symptoms of LEMS. […] Treatment usually consists of chemotherapy, with radiation therapy in those with limited disease. […] Firdapse is the only FDA-approved treatment for LEMS. Firdapse works in the presynaptic neuromuscular junction to increase the release of acetylcholine helping to improve muscle function and relieve/reduce the symptoms of LEMS. […] Some evidence supports the use of intravenous immunoglobulin (IVIG). Immune suppression tends to be less effective than in other autoimmune diseases. Prednisolone (a glucocorticoid or steroid) suppresses the immune response, and the steroid-sparing agent azathioprine may replace it once therapeutic effect has been achieved. IVIG may be used with a degree of effectiveness. Plasma exchange (or plasmapheresis), the removal of plasma proteins such as antibodies and replacement with normal plasma, may provide improvement in acute severe weakness. Plasma exchange is less effective than in other related conditions such as myasthenia gravis, and additional immunosuppressive medication is often needed.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS) Treatment & Management: Approach Considerations, Initial Management, Treatment of Underlying Malignancy

  https://emedicine.medscape.com/article/1170810-treatment

  Individually tailor therapy for Lambert-Eaton myasthenic syndrome (LEMS) on the basis of severity of weakness, underlying disease(s), life expectancy, and response to previous treatment. Therapy is best coordinated with the primary care physician and appropriate consultants. […] If an underlying neoplasm is present (eg, small cell lung cancer [SCLC]), initial treatment should be aimed at the neoplasm because weakness frequently improves with effective cancer therapy. No further LEMS treatment may be necessary in some patients. Typical treatments for patients with SCLC as the cause of their LEMS would include combination therapy with cisplatin and etoposide. Through both tumor modulation and its direct immunosuppressive properties, chemotherapy does seem to improve the symptoms of LEMS. […] In patients with LEMS who do not have cancer, aggressive immunotherapy should be considered.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/23202-lambert-eaton-myasthenic-syndrome-lems

  Lambert-Eaton myasthenic syndrome (LEMS) treatments include: […] Treatment of the underlying cancer. If LEMS is associated with a cancer like small-cell lung cancer, treating the cancer can help treat LEMS. Cancer treatment may include chemotherapy, radiation therapy and/or surgery based on the type of cancer and the recommendations of your healthcare providers. […] Treatments for LEMS include symptomatic treatment (medicines designed to alleviate some of the symptoms of the disorder) and immune-modulating treatments, which help to control your immune systems attack on your body. […] Amifampridine (Firdapse), Guanidine. These medications improve muscle strength. They increase the release of the neurotransmitter acetylcholine at the neuromuscular junction, improving the signaling of your muscles.

• #1 Lambert-Eaton myasthenic syndrome (LEMS) – catalystpharma.com

  https://catalystpharma.com/lems/

  Currently, amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS). […] Treatments include: […] Amifampridine, improves muscle function by stimulating the release of more acetylcholine into the synaptic cleft and enhancing neuromuscular transmission. […] When considering treatment options, which are limited, patients with LEMS should consult with a board-certified neurologist who specializes in neuromuscular diseases. […] Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

• #1 Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6799875/

  Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune-mediated neurological disorder that manifests as muscle fatigue, diminished tendon reflexes, with symptoms of cholinergic overactivity. […] Multiple treatment options have been introduced in the past and, recently, a new drug, amifampridine, has been approved by the Food and Drug Administration (FDA) for the treatment of weakness associated with these patients. […] The treatment option can be characterized depending upon its therapeutic impact on improving weakness in patients. […] The main therapeutic focus in LEMS is to improve neuromuscular transmission. […] 3,4-DAP binds to the VGCC, causing them to remain open for a longer duration by blocking presynaptic potassium channels. […] Amifampridine phosphate is the salt form of the 3-4-DAP base and it is more stable.

• #1 New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA! – Patient Worthy

  https://patientworthy.com/2018/12/03/new-treatment-lamberteaton-mysathenic-syndrome-approved-fda/

  Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune disorder. […] Firdapse, created by Catalyst Pharmaceuticals, has just been approved by the FDA as a new treatment for LEMS! […] Firdapse is administered orally by 10mg tablets. It’s a channel blocker that slows repolarization of the presynaptic membrane. It allows for a greater release of ACh into the synaptic cleft which improves muscle function. […] Now, Firdapse can officially be prescribed for adults with the condition. Its been approved for use in both the United States and the European Union and it should be readily available by early 2019. […] The efficacy of Firdapse was determined through two phase three clinical trials. Patients in the trials placed on Firdapse showed significant improvements in muscle function. It also reduced muscle weakness. These improvements were rapid and sustained. […] The approval of Firdapse for use in both the United States and the European Union is certainly noteworthy and looking forward, we’re excited to seeing what other diseases Firdapse may prove efficacious for.

• #1 Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6799875/

  The starting dose of amifampridine prescribed for adults is 15-30 mg orally three times a day. The maximum approved daily dose is 80 mg a day. The US Foods and Drug Administration (FDA) approved the use of amifampridine in November 2018 for adults (Firdapse). […] If amifampridine is not available or tolerated, then guanidine can be advised with or without pyridostigmine in low doses (1000 mg/day) because of its toxicity profile. […] Pyridostigmine has been advised in the treatment of moderate to severe weakness along with guanidine. […] For refractory weakness, patients can go for IVIG, prednisone, or other immunosuppressive agents. […] Rituximab and plasma exchange have also been proven to be beneficial in some refractory cases. […] The treatment options are primarily focused to improve the symptoms, primarily the weakness.

• #1 :: JCN :: Journal of Clinical Neurology

  https://thejcn.com/DOIx.php?id=10.3988/jcn.2024.0018

  The FDA approved 3,4-DAPP (Firdapse, CP) for LEMS in 2018. […] The recommended maximum dosage of amifampridines (3,4-DAP and 3,4-DAPP) is 80 mg/day, divided into three or four times daily due to their shorter half-life. […] A liberal amount of pyridostigmine may be used to supplement amifampridines for long-term administration. […] Amifampridines have been demonstrated to be effective and safe drugs for symptomatic treatment without serious side effects in both adults and children as long as the appropriate dosage is administered. Thus, these should be the drugs of choice for symptomatic treatment in pediatric LEMS. […] Amifampridines were approved by the FDA in 2022 for the symptomatic treatment of LEMS for adults as well as children.

• #1 Treatment for Lambert-Eaton myasthenic syndrome | Cochrane

  https://www.cochrane.org/CD003279/NEUROMUSC_treatment-for-lambert-eaton-myasthenic-syndrome

  Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction that causes muscle weakness (most commonly in the upper arms and legs). One of the main treatments is 3,4-diaminopyridine which increases the release of acetylcholine. Four small randomised controlled trials involving 54 participants in total showed that 3,4-diaminopyridine improves muscle strength. […] A single trial involving nine participants showed that intravenous immunoglobulin also improved muscle strength up to 8 weeks from treatment. Other possible treatments such as plasma exchange, steroids and immunosuppressive agents have not been tested in randomised controlled trials. Further trials of these treatments are needed. […] Limited but moderate to high quality evidence from randomised controlled trials showed that over days 3,4-diaminopyridine, or for up to 8 weeks IVIg, improved muscle strength scores and CMAP amplitudes in participants with Lambert-Eaton myasthenic syndrome. Other possible treatments have not been tested in randomised controlled trials.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/23202-lambert-eaton-myasthenic-syndrome-lems

  Pyridostigmine (Mestinon). Pyridostigmine helps prevent the breakdown of acetylcholine at the neuromuscular junction. This helps increase the signaling of acetylcholine to improve muscle strength. Pyridostigmine is sometimes taken with amifampridine to improve muscle function and treat dry mouth, dry eyes, constipation, impotence and decreased sweating that occurs with LEMS. Using pyridostigmine to treat LEMS is an off-label use. This means its not approved by the U.S. Food and Drug Administration (FDA) for this condition. […] Immunosuppressants. These medications help hold back your immune systems defensive action. Your healthcare provider may prescribe these medications if others arent managing your symptoms. An example of an immunosuppressant is prednisone, given with or without azathioprine or cyclosporine.

• #1 Lambert-Eaton Myasthenic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507891/

  Guanidine: This compound enhances ACh release following a nerve action potential. Guanidine should be considered only when amifampridine is unavailable due to its significant adverse effects and potential renal toxicity. The recommended adult dosage is 1 g daily. […] In cases where patients continue to have an enduring weakness that does not respond to symptomatic treatments, it becomes necessary to consider immunomodulating or immunosuppressive therapies, some of which are mentioned below. […] Intravenous immune globulin (IVIG): IVIG is the primary treatment option for refractory cases. Despite its uncertain mechanism of action, it is believed to function by neutralizing autoantibodies and regulating autoreactive B cells. The usual regimen involves administering 2 g/kg over 2 to 5 days.

• #1 IVIG for Lambert-Eaton Myasthenic Syndrome – AmeriPharma® Specialty Care

  https://ameripharmaspecialty.com/ivig/ivig-for-lambert-eaton-myasthenic-syndrome/

  Several case reports and randomized controlled trials have shown the beneficial effects of IVIG therapy in patients with LEMS. LEMS patients experience significant muscle improvement after receiving IVIG treatment as a first-line treatment. […] IVIG therapy is considered a first-line treatment for LEMS in people with refractory patterns of weakness or when traditional therapy does not work well. For example, a case report of a 34-year-old woman with progressive limb weakness who received IVIG treatment showed improvement in muscle strength. […] Studies show that IVIG therapy can be used as a short and long-term treatment in patients with LEMS, especially when immunosuppressive drugs are not effective. […] IVIG therapy is used to treat rapidly progressive symptoms of Lambert-Eaton myasthenic syndrome (LEMS). In patients with LEMS, IVIG neutralizes autoantibodies attacking the nerve endings and inhibits the activity of autoreactive B-cells. Through immune system modulation, IVIG helps to reduce the severity of symptoms and improves muscle strength in patients with LEMS.

• #1 Medical Management – Lambert-Eaton Myasthenic Syndrome (LEMS) – Diseases | Muscular Dystrophy Association

  https://www.mda.org/disease/lambert-eaton-myasthenic-syndrome/medical-management

  Intravenous immunoglobulin (IVIG) therapy can be used to block the binding of antibodies. […] For individuals who need additional therapy, immunosuppression or immune modulation is usually the next step. […] IVIG is usually preferred, with benefits that peak at two to four weeks. IVIG therapy is essentially an injection of nonspecific antibody (immunoglobulin) that might work by dialing down the immune system’s production of its own antibodies, much as warm air tells a thermostat to stop pumping out heat.

• #1 Lambert-Eaton syndrome Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/lambert-eaton-syndrome

  The main goals of treatment are to: […] Plasma exchange, or plasmapheresis, is a treatment that helps remove from the body any harmful proteins (antibodies) that are interfering with nerve function. This involves removing blood plasma that contains the antibodies. Other proteins (such as albumin) or donated plasma are then infused into the body. […] Another procedure involves using intravenous immunoglobulin (IVIg) to infuse a large amount of helpful antibodies directly into the bloodstream. […] Medicines that may also be tried include: […] Medicines that suppress the immune system’s response […] Anticholinesterase medicines to improve muscle tone (although these are not very effective when given alone) […] Medicines that increase the release of acetylcholine from nerve cells.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS) Treatment & Management: Approach Considerations, Initial Management, Treatment of Underlying Malignancy

  https://emedicine.medscape.com/article/1170810-treatment

  The initial pharmacotherapy for LEMS is with agents that increase the transmission of acetylcholine (ACh) across the neuromuscular junction, either by increasing the release of ACh or by decreasing the action of acetylcholinesterase. […] If these treatments are not effective and the patient has relatively mild weakness, determine if aggressive immunotherapy is justified. […] PEX produces improvement in many patients with LEMS. Improvement is temporary unless the patient is also receiving immunosuppression. […] IVIg, given in a course of 2 g/kg over 25 days, also induces clinically significant temporary improvement in many patients.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/23202-lambert-eaton-myasthenic-syndrome-lems

  Plasma exchange. In this procedure, a machine separates the liquid part of your blood (plasma) from blood cells. Your antibodies are in your plasma. After separation, your blood is returned to your body. Your healthcare provider may consider this treatment if you have severe symptoms that need immediate attention. […] Immunoglobulins. In some individuals, high-dose immunoglobulin therapy may help keep the disease from getting worse. […] There isnt a cure for Lambert-Eaton myasthenic syndrome. Treatment for an underlying cancer associated with LEMS has been shown to improve LEMS-related symptoms. Immunosuppressive drugs can help control the autoimmune attack, as well as control symptoms along with symptomatic treatments that improve muscle strength by increasing the amount of acetylcholine at the nerve endings. […] If you have LEMS without cancer, you can expect a near-normal length of life. If you have LEMS and a cancer that was found early and managed, your symptoms may improve over time (but not to full recovery).

• #1

  https://scholars.duke.edu/publication/1498400

  Purpose of review: This article reviews the current treatment strategies for patients with Lambert-Eaton myasthenic syndrome (LEMS) including potassium channel blockers, immunosuppressant therapies, and management of dysautonomia. […] The primary treatment option for LEMS remains amifampridine, and the efficacy of both FDA-approved formulations has been demonstrated in high-quality clinical trials. Other immunosuppressant treatments, such as corticosteroids, azathioprine, mycophenolate mofetil, and rituximab, can be used when amifampridine is unavailable, are contraindicated, or do not fully control patient symptoms. For the management of acute exacerbations or severe disease, IVIg or plasma exchange can be considered. High-quality evidence supporting the use of immunosuppressive and immunomodulatory treatments in LEMS patients is generally lacking. Treatment response can be monitored by bedside exams and the Triple Timed Up-and-Go test.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS) Medication: Potassium Channel Blockers, Cholinergic Agonists, Immunosuppressants, Blood products

  https://emedicine.medscape.com/article/1170810-medication

  Immunosuppressants should be added for more sustained improvement. Prednisone and azathioprine, the most frequently used immunosuppressants, can be used alone or in combination. […] IVIg, given in a course of 2 g/kg over 25 days, also induces clinically significant temporary improvement in many patients. […] If the therapies already described are ineffective, more aggressive immunotherapy may be indicated. Therapy can take the form of plasma exchange or high-dose IVIg, with the potential for more long-term immunosuppression, usually with prednisone or azathioprine. […] Prednisone is used as an immunosuppressant in the treatment of autoimmune disorders. The combination of corticosteroid therapy with azathioprine may be more effective than steroid monotherapy. […] Azathioprine inhibits mitosis and cellular metabolism by antagonizing purine metabolism and inhibiting synthesis of DNA, RNA, and proteins. These effects may inhibit formation of immune cells, possibly reducing activity of immune system. […] Agents in this category may be used to improve clinical and immunologic aspects of LEMS. They may decrease autoantibody production and increase solubilization and removal of immune complexes. IVIg can be an effective treatment for LEMS.

• #1 Lambert-Eaton Myasthenic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507891/

  Steroids and other immunosuppressive agents: Although azathioprine, mycophenolate, and cyclosporine may be considered for specific cases, their efficacy is generally lower than IVIG. In addition, the potential for significant adverse effects often limits their widespread use. […] Rituximab: This monoclonal antibody targets CD20 receptors found on B lymphocytes. Theoretically, it is effective against all B-cell-mediated diseases, including LEMS. Nevertheless, data supporting its more extensive utilization is insufficient. […] Plasma exchange: In certain refractory cases, plasma exchange holds the potential to offer benefits.

• #1 Lambert-Eaton myasthenic syndrome: Treatment and prognosis – UpToDate

  https://www.uptodate.com/contents/lambert-eaton-myasthenic-syndrome-treatment-and-prognosis

  Lambert-Eaton myasthenic syndrome: Treatment and prognosis […] This topic will review treatment for LEMS. […] The first priority in the management of LEMS is to evaluate for a primary underlying malignancy. Treatment of the underlying malignancy may be the only intervention necessary to produce improvement in neurologic symptoms. […] Initial symptomatic therapy includes Amifampridine (3,4-diaminopyridine) for moderate to severe weakness, and Pyridostigmine if 3,4-DAP is not available. […] For refractory weakness, intravenous immune globulin is recommended for most patients, with alternative options including Prednisone, other oral immunosuppressive agents, Rituximab, and plasma exchange.

• #1 Orphanet: Lambert-Eaton myasthenic syndrome

  https://www.orpha.net/en/disease/detail/43393

  There is no cure for LEMS and treatment is mainly symptomatic. This includes 3, 4-diaminopyridine phosphate (DAP) which is usually well tolerated and effective. […] If symptomatic treatment is insufficient, immunosuppressive therapy with prednisone, alone or in combination with azathioprine, can achieve long-term control of the disorder. Plasmapheresis and high dose administration of intravenous immunoglobulins (IVIGs) have a short effect. An effective treatment against any tumor present is mandatory, both to control the tumor and to improve the clinical symptoms of LEMS. […] In general, LEMS responds well to symptomatic and immunosuppressive treatments.

• #1 LEMS Treatment | LEMS Aware HCPLEMS Aware logoLEMS Aware on LinkedInLEMS Aware on TwitterLEMS Aware on FacebookCatalyst Logo

  https://www.lemsawarehcp.com/lems-treatment/

  Clinical data suggest that cholinesterase inhibitors, such as pyridostigmine, are generally not effective as monotherapies for LEMS. […] Recommended for flares or when symptomatic treatment is not sufficient. […] In addition, limited clinical data suggest that IVIG therapies may provide a short-term benefit for adult patients with LEMS. […] Symptomatic treatment of LEMS is recommended in addition to anticancer therapy for patients with cancer-associated LEMS. […] In a case study that included 16 patients, treatment with amifampridine was continued in conjunction with antineoplastic therapy.

• #1 :: JCN :: Journal of Clinical Neurology

  https://thejcn.com/DOIx.php?id=10.3988/jcn.2024.0018

  Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome […] Efficacy of amifampridine (3,4-DAP and 3,4-diaminopyridine phosphate [3,4-DAPP]) for symptomatic treatment in LEMS was proven by seven randomized studies in 3,4-DAP and two randomized studies in 3,4-DAPP. […] Amifampridine can be safely used as long the daily dose is less than 80 mg a day for adult LEMS patients and less than 30 mg a day for pediatric LEMS patients. […] Amifampridines can be supplemented with a liberal amount of pyridostigmine for long term usage. […] Amifampridines are proven to be effective and safe drugs for the symptomatic treatment without serious side reaction in adults as well as in children as long as the dosage is properly adhered.

• #1 Disease Education | LEMS AwareLEMS Aware on InstagramLEMS Aware on Facebook

  https://www.lemsaware.com/

  LEMS Aware was created to deliver relevant information, resources, and connections to patients and caregivers who may be living with or affected by LEMS. […] Learn more about LEMS symptoms and how you can take charge of your health to get the proper diagnosis and treatment you need. […] For some patients, LEMS symptoms are an important early warning sign that alerts doctors to screen for cancer and get an earlier start on treatment. […] LEMS Pregnancy Registry: In conjunction with the FDA, Catalyst Pharmaceuticals has created a registry to collect information about the safety of LEMS treatment in the event of pregnancy. […] Consult with your doctor regarding specific questions around your current LEMS treatment and COVID-19 vaccination. […] Visit the Diagnosis and Treatment page to learn more about LEMS experts who can put you on the path to feeling better. […] Diagnosis and treatment are the most important milestones on the journey to feeling better, but there are other things that you can do to help manage your condition.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Treatment and more

  https://www.verywellhealth.com/lambert-eaton-myasthenic-syndrome-lems-5100988

  Tumor surveillance is another key part of treatment. Even if your imaging tests didnt show any signs of cancer, its possible that you might have a very small cancer that just didnt show up on the test. […] For this reason, its recommended that most people with LEMS get repeat imaging tests done of their chests, at least for a while. This can ensure that a potential cancer is detected and treated as soon as possible.

• #1

  https://scholars.duke.edu/display/pub726099

  A high index of suspicion is essential in arriving at the correct diagnosis of Lambert-Eaton myasthenic syndrome (LEMS). […] Successful treatment of the underlying cancer leads to improvement in many patients. More than 85% of patients have clinically significant benefit from 3,4-diaminopyridine (DAP). […] If severe weakness persists despite DAP, immunotherapy should be considered. Plasma exchange and high-dose immunoglobulin induce transient improvement in many patients, but function rarely becomes normal. Combinations of prednisone, azathioprine, or cyclosporine have been used with variable success. Improvement, if any, occurs only after many months and requires chronic administration of immunosuppressive medications at significant doses. The long-term prognosis in LEMS is determined by the presence of cancer or other autoimmune disease.

• #1 LEMS Treatment | LEMS Aware HCPLEMS Aware logoLEMS Aware on LinkedInLEMS Aware on TwitterLEMS Aware on FacebookCatalyst Logo

  https://www.lemsawarehcp.com/lems-treatment/

  There is currently no cure for Lambert-Eaton myasthenic syndrome (LEMS); however, there are treatments available that can significantly reduce the impact of LEMS on patients’ lives. […] In general, the goals for LEMS treatment include: Restoration/maintenance of muscle function and strength, Improved patient mobility and independence, Improved quality of life, Assessing for/treating associated malignancies. […] Increase availability of ACh (eg, amifampridine) or inhibit degradation of ACh (eg, pyridostigmine) in the neuromuscular junction. […] In a double-blind, randomized, controlled trial comparing the efficacy of amifampridine and pyridostigmine in patients with LEMS, only amifampridine consistently produced significant improvements in muscle strength and compound muscle action potential (CMAP) amplitudes.

• #1 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  LEMS treatment includes symptomatic treatment and immunotherapies, depending on the clinical course and severity. Because more than half of people with LEMS have an underlying malignancy, multidisciplinary care in collaboration with oncology is needed. […] The most commonly used symptomatic treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). 3,4-DAP helps to increase release of ACh from the presynaptic nerve terminal by blocking potassium channels, which results in prolonged depolarization, a longer open time for calcium channels, and subsequent increase in presynaptic terminal release of ACh. Use of 3,4-DAP for treatment of LEMS has been described since the 1980s in small series. Randomized controlled trials have unequivocally demonstrated the benefits of 3,4-DAP in LEMS. Dosing in adults is typically started at 10 mg 3 times daily, with a maximum daily dosage of 80 mg to avoid risk of seizure. Treatment with intravenous immunoglobulin, plasmapheresis, or immunosuppression can be considered, typically for severe symptoms or poor response to symptomatic treatment. […] Treatment consists of management of the underlying cancer in paraneoplastic cases, symptomatic therapy with 3,4-DAP, and consideration of intravenous immunoglobulin, plasma exchange, or immunosuppression in severe or refractory cases.

• #1 Effective Treatment Of Lambert Eaton Myasthenic Syndrome

  https://drchandrilchugh.com/lambert-eaton-myasthenic-syndrome/effective-treatment-of-lambert-eaton-myasthenic-syndrome/

  Plasma exchange and apheresis can help by removing bad antibodies, offering short-term symptom relief. […] For LEMS linked to small-cell lung cancer, tackling the cancer is key. Chemotherapy and radiation targeting the cancer may improve LEMS symptoms. […] A mix of treatments is often needed for LEMS. Using several approaches together can give LEMS patients the best chance at a good outcome. […] Managing LEMS for the long run means checking on it often. […] Besides medicines, supportive care is vital in LEMS treatment. This includes physical and occupational therapy. […] Current clinical trials and research are vital for improving LEMS knowledge and treatment. […] Treating Lambert-Eaton myasthenic syndrome (LEMS) effectively needs a broad approach. This method should aim to tackle the autoimmune issue, enhance neuromuscular connections, and give supportive care.

• #1 New Lambert-Eaton myasthenic syndrome (LEMS) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=61

  Emerging experimental therapies such as rituximab, a monoclonal antibody targeting B cells, show promise in refractory or autoimmune-associated cases of LEMS. […] The optimal treatment choice for LEMS depends on multiple factors, including patient age, severity of symptoms, comorbidities, potential side effects, and medication accessibility. […] Regular follow-up and ongoing collaboration between neurologists, oncologists, and other healthcare providers are critical to managing LEMS effectively.

• #2 Lambert-Eaton myasthenic syndrome: Treatment and prognosis – UpToDate

  https://www.uptodate.com/contents/lambert-eaton-myasthenic-syndrome-treatment-and-prognosis

  Lambert-Eaton myasthenic syndrome: Treatment and prognosis […] This topic will review treatment for LEMS. […] The first priority in the management of LEMS is to evaluate for a primary underlying malignancy. Treatment of the underlying malignancy may be the only intervention necessary to produce improvement in neurologic symptoms. […] Initial symptomatic therapy includes Amifampridine (3,4-diaminopyridine) for moderate to severe weakness, and Pyridostigmine if 3,4-DAP is not available. […] For refractory weakness, intravenous immune globulin is recommended for most patients, with alternative options including Prednisone, other oral immunosuppressive agents, Rituximab, and plasma exchange.

• #2 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  LEMS treatment includes symptomatic treatment and immunotherapies, depending on the clinical course and severity. Because more than half of people with LEMS have an underlying malignancy, multidisciplinary care in collaboration with oncology is needed. […] The most commonly used symptomatic treatment in LEMS is 3,4-diaminopyridine (3,4-DAP). 3,4-DAP helps to increase release of ACh from the presynaptic nerve terminal by blocking potassium channels, which results in prolonged depolarization, a longer open time for calcium channels, and subsequent increase in presynaptic terminal release of ACh. Use of 3,4-DAP for treatment of LEMS has been described since the 1980s in small series. Randomized controlled trials have unequivocally demonstrated the benefits of 3,4-DAP in LEMS. Dosing in adults is typically started at 10 mg 3 times daily, with a maximum daily dosage of 80 mg to avoid risk of seizure. Treatment with intravenous immunoglobulin, plasmapheresis, or immunosuppression can be considered, typically for severe symptoms or poor response to symptomatic treatment. […] Treatment consists of management of the underlying cancer in paraneoplastic cases, symptomatic therapy with 3,4-DAP, and consideration of intravenous immunoglobulin, plasma exchange, or immunosuppression in severe or refractory cases.

• #2 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials | BMC Neurology | Full Text

  https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02405-3

  Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of neuromuscular transmission. The objective was to examine the efficacy and safety of 3,4-diaminopyridine (3,4-DAP) in patients with LEMS. […] Six randomised controlled trials (RCTs) involving 115 patients with LEMS were included. QMG score showed a significant decrease (improvement) of 2.76 points (95% CI, -4.08 to -1.45, p0.001) after treatment with 3, 4-DAP. Moreover, the overall mean CMAP amplitude improved significantly in LEMS patients with 3, 4-DAP treatment, compared with placebo treatment (mean difference 1.34 mV, 95% CI, 0.98 to 1.70, p0.001). […] The pooled results of RCTs demonstrated with moderate to high evidence that 3,4-DAP has a significant effect on LEMS treatment, with improvements in muscle strength score and CMAP amplitude.

• #2 Rituximab: effective treatment in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome – Institut de Myologie

  https://www.institut-myologie.org/en/2013/06/27/rituximab-effective-treatment-in-a-case-of-seronegative-non-paraneoplastic-lambert-eaton-myasthenic-syndrome/

  Lambert-Eaton myasthenic syndrome is a rare and autoimmune presynaptic disorder of the neuromuscular junction, due in 85% of cases to autoantibodies directed against voltage-gated calcium channels. […] Symptomatic treatment is based on 3,4-diaminopyridine. No etiological treatment has proven its efficacy in both paraneoplastic and non-paraneoplastic Lambert-Eaton myasthenic syndrome. […] The authors conclude that rituximab is an effective and well-tolerated treatment in this case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome. Its indication should be discussed when conventional immunosuppressive therapy fails in both seropositive and seronegative patients.

Zobacz więcej